Characterization of peripheral artery disease and associations with traditional risk factors, mobility, and biomarkers in the project baseline health study.

Autor: Kercheval JB; Department of Medicine, Duke University School of Medicine, Durham, NC., Narcisse DI; Department of Medicine, Duke University School of Medicine, Durham, NC., Nguyen M; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC., Rao SV; Department of Medicine, NYU Grossman School of Medicine, New York, NY., Gutierrez JA; Department of Medicine, Duke University School of Medicine, Durham, NC; Durham VA Medical Center, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Leeper NJ; Department of Surgery, Stanford University, Stanford, CA; Division of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University, Stanford, CA., Maron DJ; Division of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University, Stanford, CA; Stanford Prevention Research Center, Stanford University, Stanford, CA., Rodriguez F; Division of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University, Stanford, CA., Hernandez AF; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Mahaffey KW; Division of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University, Stanford, CA; Stanford Center for Clinical Research, Stanford University, Stanford, CA., Shah SH; Department of Medicine, Duke University School of Medicine, Durham, NC; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC., Swaminathan RV; Department of Medicine, Duke University School of Medicine, Durham, NC; Durham VA Medical Center, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. Electronic address: rajesh@duke.edu.
Jazyk: angličtina
Zdroj: American heart journal [Am Heart J] 2024 Sep; Vol. 275, pp. 183-190. Date of Electronic Publication: 2024 Jul 03.
DOI: 10.1016/j.ahj.2024.06.010
Abstrakt: Background: There is a dearth of research on immunophenotyping in peripheral artery disease (PAD). This study aimed to describe the baseline characteristics, immunophenotypic profile, and quality of life (QoL) of participants with PAD in the Project Baseline Health Study (PBHS).
Methods: The PBHS study is a prospective, multicenter, longitudinal cohort study that collected clinical, molecular, and biometric data from participants recruited between 2017 and 2018. In this analysis, baseline demographic, clinical, mobility, QoL, and flow cytometry data were stratified by the presence of PAD (ankle brachial index [ABI] ≤0.90).
Results: Of 2,209 participants, 58 (2.6%) had lower-extremity PAD, and only 2 (3.4%) had pre-existing PAD diagnosed prior to enrollment. Comorbid smoking (29.3% vs 14%, P < .001), hypertension (54% vs 30%, P < .001), diabetes (25% vs 14%, P = .031), and at least moderate coronary calcifications (Agatston score >100: 32% vs 17%, P = .01) were significantly higher in participants with PAD than in those with normal ABIs, as were high-sensitivity C-reactive protein levels (5.86 vs 2.83, P < .001). After adjusting for demographic and risk factors, participants with PAD had significantly fewer circulating CD56-high natural killer cells, IgM+ memory B cells, and CD10/CD27 double-positive B cells (P < .05 for all).
Conclusions: This study reinforces existing evidence that a large proportion of PAD without claudication may be underdiagnosed, particularly in female and Black or African American participants. We describe a novel immunophenotypic profile of participants with PAD that could represent a potential future screening or diagnostic tool to facilitate earlier diagnosis of PAD.
Gov Identifier: NCT03154346, https://clinicaltrials.gov/ct2/show/NCT03154346.
Competing Interests: Conflict of interest JAG reports research funding from the Department of Veterans Affairs. NL reports grants from the NIH and AHA. He is a director of Bitterroot Bio and receives consulting fees unrelated to this study. FR reports consulting relationships with Healthpals, Amgen, NovoNordisk (CEC), and Novartis outside the submitted work. AH reports grants from Verily; grants and personal fees from AstraZeneca, Amgen, Bayer, Merck, and Novartis; and personal fees from Boston Scientific outside the submitted work. KM reports grants from Verily, Afferent, the American Heart Association (AHA), Cardiva Medical Inc, Gilead, Luitpold, Medtronic, Merck, Eidos, Ferring, Apple Inc, Sanifit, and St. Jude; grants and personal fees from Amgen, AstraZeneca, Bayer, CSL Behring, Johnson & Johnson, Novartis, and Sanofi; and personal fees from Anthos, Applied Therapeutics, Elsevier, Inova, Intermountain Health, Medscape, Mount Sinai, Mundi Pharma, Myokardia, Novo Nordisk, Otsuka, Portola, SmartMedics, and Theravance outside the submitted work. RVS reports advisory board fees from Philips; research support from ACIST Medical. The other authors have no conflicts of interest to disclose.
(Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: